Experimental Alzheimer's drug aims to quiet Brain's toxic tau
NCT ID NCT06372821
First seen Jan 28, 2026
Summary
This early-stage trial tests a drug called NIO752, given via spinal injection, to see if it can reduce production of tau protein in the brain. Tau buildup is linked to Alzheimer's damage. Ten people with mild to moderate Alzheimer's will receive either NIO752 or a placebo, and researchers will measure tau levels using a special labeling technique. The goal is to see if the drug safely lowers tau production.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University College London Hospitals NHS Foundation Trust
RECRUITINGLondon, NW1 2PG, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Washington University in St. Louis
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NIO752 (antisense oligonucleotide)
What this could lead to
If it works, this could point toward a treatment that slows or stops Alzheimer's by reducing harmful tau buildup in the brain.
What could go wrong
This is a very early Phase 1 trial with only 10 participants, so it is too soon to know if the drug is safe or effective. The approach is experimental and may not work in larger groups.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.